Biothera Pharmaceuticals Presents Updated Phase 2 Data for Chemo-refractory Triple Negative Breast Cancer Patients at San Antonio Breast Cancer Symposium
11. Dezember 2019 18:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today that updated response and clinical benefit data from its ongoing Phase 2 study in chemo-refractory...
Biothera Pharmaceuticals Phase 2 Triple Negative Breast Cancer Data Selected for Spotlight Session at San Antonio Breast Cancer Symposium
04. Dezember 2019 09:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that response and clinical benefit data from its Phase 2 study of dectin-1 agonist Imprime PGG in...
Biothera Pharmaceuticals to Present Immune Pharmacodynamic Data (IPD) Showing Immune Activation in Phase 2 Melanoma and Triple Negative Breast Cancer Study
08. November 2019 07:00 ET
|
Biothera Pharmaceuticals, Inc.
Two Late-Breaking Poster Presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Imprime PGG-induced IPD Changes Associated with Stable Disease, Progression-Free Survival and...
Biothera Pharmaceuticals to Present Immune Pharmacodynamic and Survival Data from Phase 2 Melanoma and Triple Negative Breast Cancer Study
05. November 2019 10:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. will present two late-breaking posters highlighting immune pharmacodynamic data from its Phase 2 clinical study in...
Biothera Pharmaceuticals Presents Clinical Data from Phase 2 Study Evaluating the Combination of Imprime PGG and Merck’s KEYTRUDA in Triple Negative Breast Cancer at 2019 ASCO Annual Meeting
01. Juni 2019 09:00 ET
|
Biothera Pharmaceuticals, Inc.
Imprime PGG is a dectin receptor agonist that triggers anti-cancer immune responsesIMPRIME 1 study enrolled 44 previously treated, metastatic triple negative breast cancer (TNBC) patients15.9% Overall...
Biothera Pharmaceuticals to Present Clinical Data from Phase 2 Triple Negative Breast Cancer Study at ASCO 2019 Annual Meeting
16. Mai 2019 10:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., May 16, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc., which is developing a dectin receptor agonist drug known as Imprime PGG, announced today that it will present primary...
Biothera Pharmaceuticals Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca
05. September 2018 09:15 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today a clinical collaboration with AstraZeneca to evaluate whether the combination of Biothera’s Imprime...
Biothera Pharmaceuticals Appoints Andrew D.C. LaFrence Chief Financial Officer
16. Mai 2018 16:10 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., May 16, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc., announced the appointment of Andrew D.C. LaFrence, CPA as Senior Vice President and Chief Financial Officer, effective...
Biothera Pharmaceuticals Presents Translational Data from Ongoing Clinical Trials Showing Imprime PGG in Combination with Merck’s KEYTRUDA® (pembrolizumab) Drives Innate and Adaptive Immune Responses in Tumors
16. April 2018 09:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., April 16, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced the presentation of new translational data from ongoing phase 2 clinical trials combining Biothera’s...
Preclinical Data Showing Synergy of Biothera Pharmaceuticals’ Imprime PGG and a CD40 Agonist in a Pancreatic Cancer Model Presented at Keystone Symposia
26. März 2018 10:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., March 26, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. and the Abramson Cancer Center of the University of Pennsylvania announced today the presentation of new preclinical...